GSK PLC Sponsored ADR (GSK) to Distribute Quarterly Dividend of $0.45 on October 8th

GSK PLC Sponsored ADR (NYSE:GSK) declared a quarterly dividend on Tuesday, July 28th. Investors of record on Friday, August 14th will be paid a dividend of 0.4515 per share by the pharmaceutical company on Thursday, October 8th. This represents a c) dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend is Friday, August 14th. This is a 2.6% increase from GSK’s previous quarterly dividend of $0.44.

GSK has decreased its dividend by an average of 0.1%per year over the last three years. GSK has a dividend payout ratio of 37.0% indicating that its dividend is sufficiently covered by earnings. Research analysts expect GSK to earn $5.16 per share next year, which means the company should continue to be able to cover its $1.79 annual dividend with an expected future payout ratio of 34.7%.

GSK Stock Performance

Shares of NYSE GSK opened at $53.15 on Thursday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.52 and a current ratio of 0.79. GSK has a 1 year low of $36.75 and a 1 year high of $61.69. The company’s fifty day moving average price is $51.72 and its 200 day moving average price is $53.48. The company has a market capitalization of $107.50 billion, a PE ratio of 16.62, a price-to-earnings-growth ratio of 3.42 and a beta of 0.35.

More GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Second-quarter results exceeded expectations. GSK reported adjusted earnings of approximately $1.34–$1.36 per share versus a $1.27 consensus, while revenue reached about $11.14 billion, up 5.3% year over year and ahead of estimates. Vaccine performance was a key contributor. GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
• Positive Sentiment: Cost reductions could strengthen the pipeline. The company plans to achieve approximately $2.52 billion in annual savings by 2029 and reinvest the proceeds in more than 20 late-stage study starts, supporting its efforts to offset upcoming patent expirations. GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline
• Positive Sentiment: GSK reaffirmed its 2026 outlook and provided adjusted EPS guidance of roughly $4.90–$5.00, above the consensus estimate. Its partner Hansoh’s experimental cancer drug also met the main goal in a late-stage bone-cancer trial, adding potential value to the oncology pipeline. GSK, Hansoh’s cancer drug meets main goal of bone cancer trial
• Positive Sentiment: The quarterly dividend increased 2.6% to $0.4515 per share, supporting GSK’s income appeal with an annualized yield of about 3.4%.
• Positive Sentiment: GSK will invest £400 million in U.K. research, including a new Cambridge science hub focused partly on cancer medicines, signaling increased commitment to long-term innovation. GSK to invest £400 million in Britain over three years
• Negative Sentiment: Revenue guidance remains a concern. The 2026 revenue outlook of approximately $44.8 billion is below the roughly $45.7 billion analyst consensus, potentially limiting the upside from the earnings beat.
• Negative Sentiment: The savings plan carries execution and disruption risks. GSK plans to close its Stevenage R&D hub, affecting around 1,800 employees, while relocating research activities to Cambridge. An analyst also downgraded the stock, citing limited additional upside after its recent gains. GSK: Healthy Results, But Limited Stock Upside

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.